AUR-AFEC-TTM6-A-1-1-R-A742-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.640
- INTERFERON_ALPHA_RESPONSE+0.630
- TNFA_SIGNALING_VIA_NFKB+0.610
- ANGIOGENESIS+0.580
- INTERFERON_GAMMA_RESPONSE+0.580
- HYPOXIA+0.540
- INFLAMMATORY_RESPONSE+0.540
- IL6_JAK_STAT3_SIGNALING+0.510
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.500
- TGF_BETA_SIGNALING+0.500
Top 10 suppressed
- MYC_TARGETS_V2-0.430
- PEROXISOME-0.280
- MYC_TARGETS_V1-0.130
- E2F_TARGETS-0.120
- SPERMATOGENESIS-0.120
- BILE_ACID_METABOLISM-0.110
- G2M_CHECKPOINT-0.040
- KRAS_SIGNALING_DN-0.040
- MITOTIC_SPINDLE-0.040
- UNFOLDED_PROTEIN_RESPONSE-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02601 | — | cohortA1 | 0.922 |
| 2 | EPT0509 | EPN | EPN Tumor | 0.922 |
| 3 | TCGA-CV-7433-01A-11R-2132-07 | — | — | 0.907 |
| 4 | ERR2208908 | — | — | 0.907 |
| 5 | 17-026K4_Bladder | — | — | 0.904 |
| 6 | s_150324_4b | EPN | Posterior Fossa EPN | 0.903 |
| 7 | MDT-AP-2887 | Med | Medulloblastoma | 0.899 |
| 8 | SRR10900576 | — | — | 0.896 |
| 9 | MDT-AP-2021 | Med | Medulloblastoma | 0.896 |
| 10 | R316 | — | — | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.640 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.610 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.580 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| HYPOXIA | 0.540 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.540 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.510 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.500 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| COAGULATION | 0.470 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| APOPTOSIS | 0.450 | Idelalisib | — uncovered |
| COMPLEMENT | 0.440 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.440 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.420 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.370 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |